Garcinol has been reported to inhibit NF-κB/Twist1 signaling activated by paclitaxel and downregulate the expression level of EMT-TFs, thus significantly improving the efficacy of paclitaxel in breast cancer in the orthotopic breast cancer model (215). This evidence concerns the gene TWIST1 and breast carcinoma.